(redirected from Biosimilars)
Also found in: Medical.


Highly similar in function and effect to an existing biological product, especially to a biologic that has already been clinically tested and approved for use.
A biological product that is biosimilar to an existing product, especially to a biologic.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
M2 PRESSWIRE-August 30, 2019-: Biosimilars Market 2019 will Boom with Key Players AMEGA Biotech S.A., Merck Sharp & Dohme, Pfizer, Dr.
London, United Kingdom, August 23, 2019 --( The 10th Annual Biosimilars conference is set to take place on 25th and 26th September in London, UK.
Fact.MR has announced the addition of the "Retinal Biosimilars Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2026"report to their offering.
WASHINGTON -- Delayed entry of biosimilars due to patenting has cost the U.S.
Biosimilars generate savings that help manage the growing costs of Australia's health care system, particularly the PBS.
"Several years ago, Amgen made the strategic decision to invest in building a global biosimilars business, leveraging our nearly four decades of experience in developing and manufacturing best-in-class biologics," Amgen Executive Vice President of Global Commercial Operations Murdo Gordon.
* Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to treatment
Government support for biosimilars is increasing in all the leading as well as emerging markets, given the cost-saving opportunities that these products represent for national healthcare budgets.
A Biosimilars are the equivalent of an original medicine so they have the same effect and have been approved by the same standards of quality, safety and effectiveness, though they may not be identical.
Xbrane Biopharma announced on Monday that its board of directors has decided to shift the company's strategic focus of its product pipeline to biosimilars.
Credit Suisse analyst Vamil Divan reiterated an Underperform rating on AbbVie after the FDA further ramped up its focus on biosimilars. In a research note to investors, Divan said he was "intrigued" by the FDA's decision to withdraw its September 2017 Draft Guidance focused on evaluating analytical similarity with biosimilars, and believes the agency will release "more reasonable" guidance in the coming months that will expedite the approval and uptake of biosimilars.